Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus.
South Africa
adherence
drug-resistant TB/HIV
mixed-methods
person-centered care
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
05 10 2021
05 10 2021
Historique:
received:
23
06
2020
pubmed:
15
10
2020
medline:
21
10
2021
entrez:
14
10
2020
Statut:
ppublish
Résumé
In generalized drug-resistant tuberculosis (DR-TB) human immunodeficiency virus (HIV) epidemics, identifying subpopulations at high risk for treatment failure and loss to care is critically important to improve treatment outcomes and prevent amplification of drug resistance. We hypothesized that an electronic dose-monitoring (EDM) device could empirically identify adherence-challenged patients and that a mixed-methods approach would characterize treatment challenges. A prospective study of patients with DR-TB HIV on antiretroviral therapy (ART) initiating bedaquiline-containing regimens in KwaZulu-Natal, South Africa. Separate EDM devices measured adherence for bedaquiline and ART. Patients with low adherence (<85%) to both bedaquiline and ART were identified as high risk for poor outcomes. Baseline survey, study visit notes, and focus group discussions characterized treatment challenges. From December 2016-February 2018, 32 of 198 (16%) enrolled patients with DR-TB HIV were identified as dual-adherence challenged. In a multivariate model including baseline characteristics, only receiving a disability grant was significantly associated with dual nonadherence at 6 months. Mixed-methods identified treatment barriers including alcohol abuse, family conflicts, and mental health issues. Compared with adherent patients, dual-adherence-challenged patients struggled to prioritize treatment and lacked support, and dual-adherence-challenged patients experienced higher rates of detectable HIV viral load and mortality than more adherent patients. EDM empirically identified a subpopulation of patients with DR-TB HIV with dual-adherence challenges early in treatment. Mixed-methods revealed intense psychosocial, behavioral, and structural barriers to care in this subpopulation. Our data support developing differential, patient-centered, adherence support interventions focused on psychosocial and structural challenges for subpopulations of at-risk DR-TB HIV patients.
Sections du résumé
BACKGROUND
In generalized drug-resistant tuberculosis (DR-TB) human immunodeficiency virus (HIV) epidemics, identifying subpopulations at high risk for treatment failure and loss to care is critically important to improve treatment outcomes and prevent amplification of drug resistance. We hypothesized that an electronic dose-monitoring (EDM) device could empirically identify adherence-challenged patients and that a mixed-methods approach would characterize treatment challenges.
METHODS
A prospective study of patients with DR-TB HIV on antiretroviral therapy (ART) initiating bedaquiline-containing regimens in KwaZulu-Natal, South Africa. Separate EDM devices measured adherence for bedaquiline and ART. Patients with low adherence (<85%) to both bedaquiline and ART were identified as high risk for poor outcomes. Baseline survey, study visit notes, and focus group discussions characterized treatment challenges.
RESULTS
From December 2016-February 2018, 32 of 198 (16%) enrolled patients with DR-TB HIV were identified as dual-adherence challenged. In a multivariate model including baseline characteristics, only receiving a disability grant was significantly associated with dual nonadherence at 6 months. Mixed-methods identified treatment barriers including alcohol abuse, family conflicts, and mental health issues. Compared with adherent patients, dual-adherence-challenged patients struggled to prioritize treatment and lacked support, and dual-adherence-challenged patients experienced higher rates of detectable HIV viral load and mortality than more adherent patients.
CONCLUSIONS
EDM empirically identified a subpopulation of patients with DR-TB HIV with dual-adherence challenges early in treatment. Mixed-methods revealed intense psychosocial, behavioral, and structural barriers to care in this subpopulation. Our data support developing differential, patient-centered, adherence support interventions focused on psychosocial and structural challenges for subpopulations of at-risk DR-TB HIV patients.
Identifiants
pubmed: 33053186
pii: 5923372
doi: 10.1093/cid/ciaa1557
pmc: PMC8492155
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1901-e1910Subventions
Organisme : NIAID NIH HHS
ID : R01 AI114900
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI124413
Pays : United States
Organisme : FIC NIH HHS
ID : R21 TW011077
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Lancet Respir Med. 2018 Sep;6(9):653-655
pubmed: 30001995
PLoS Med. 2018 Jul 3;15(7):e1002595
pubmed: 29969463
Syst Rev. 2019 Dec 6;8(1):314
pubmed: 31810482
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
PLoS Med. 2019 Dec 10;16(12):e1002884
pubmed: 31821323
Int J Tuberc Lung Dis. 2016 Apr;20(4):430-4
pubmed: 26970149
AIDS Care. 2015;27(10):1231-40
pubmed: 26213142
Lancet Respir Med. 2018 Sep;6(9):699-706
pubmed: 30001994
Clin Infect Dis. 2006 Oct 1;43(7):939-41
pubmed: 16941380
Glob Public Health. 2014;9(9):1107-16
pubmed: 25035943
Lancet HIV. 2019 Mar;6(3):e201-e204
pubmed: 30846058
AIDS. 2017 May 15;31(8):1065-1071
pubmed: 28358730
Int J Tuberc Lung Dis. 2017 Aug 1;21(8):852-861
pubmed: 28786792
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19408
pubmed: 25724504
BMC Public Health. 2020 Jan 17;20(1):76
pubmed: 31952494
Clin Infect Dis. 2018 Oct 15;67(9):1411-1418
pubmed: 29659757
Eur Respir J. 2019 Jan 10;53(1):
pubmed: 30309972
J Acquir Immune Defic Syndr. 2018 May 1;78(1):1-8
pubmed: 29389769
PLoS Med. 2007 Jul 24;4(7):e238
pubmed: 17676945
Soc Psychiatry Psychiatr Epidemiol. 2019 Mar;54(3):387-393
pubmed: 30758540
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):34-41
pubmed: 29025483
Public Health Action. 2018 Mar 21;8(1):25-27
pubmed: 29581940
Emerg Infect Dis. 2013 Mar;19(3):416-24
pubmed: 23622055
BMC Infect Dis. 2019 Aug 16;19(1):723
pubmed: 31420021
Int J Tuberc Lung Dis. 2006 Jun;10(6):649-55
pubmed: 16776452
JMIR Mhealth Uhealth. 2018 May 17;6(5):e122
pubmed: 29773527
AIDS Behav. 2010 Dec;14(6):1340-6
pubmed: 20809380
BMC Infect Dis. 2018 Apr 11;18(1):171
pubmed: 29642874
BMJ Glob Health. 2018 Oct 11;3(5):e001018
pubmed: 30364330
AIDS. 2008 Jan 2;22(1):75-82
pubmed: 18090394
Int J Ment Health Addict. 2018 Feb;16(1):45-52
pubmed: 29632453
Int J Tuberc Lung Dis. 2012 Jan;16(1):90-7
pubmed: 22236852
Lancet HIV. 2018 Oct;5(10):e560-e568
pubmed: 30143455
Int J Tuberc Lung Dis. 2020 Jan 1;24(1):73-82
pubmed: 32005309
PLoS One. 2016 Jan 25;11(1):e0147397
pubmed: 26807933
Trials. 2020 May 5;21(1):383
pubmed: 32370774
PLoS Med. 2017 Nov 21;14(11):e1002444
pubmed: 29161256